NCT07901309|Not Yet RecruitingPhase 1/2
Loading search results
Sponsor study identifier
interventional
100
1 country
1
Study Start
October 30, 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Primary Completion
June 30, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
July 1, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Rheumatoid arthritis (RA) is a long-standing autoimmune inflammatory disease marked by continuous synovial inflammation, which contributes to progressive cartilage and bone damage, eventually resulting in joint destruction. Both inherited genetic factors and environmental exposures substantially contribute to the risk of developing the disease. Additionally, several lifestyle and biological factors including diet, cigarette smoking, hormonal influences, alcohol consumption, gut microbiota, infections, and coffee intake have been implicated in the development and progression of RA. Clinically, RA is frequently characterized by morning stiffness, pain involving the shoulder, neck, and pelvic girdle, impaired mobility, and systemic features including fever.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
July 1, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
October 22, 2026
Actual (reported)October 28, 2026
Actual (reported)October 30, 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
June 30, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
July 1, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Change in disease activity score (DAS-28CRP)
A DAS28 score \>5.1 was classified as high disease activity, 3.2 \< DAS28 ≤ 5.1 as moderate activity, and DAS28 ≤ 3.2 as low. activity, and DAS28 \<2.6 as remission
3 months
control group (n =50) that will receive conventional therapy for RA and placebo
(dapagliflozin group, n = 50) will receive dapagliflozin (10) mg once daily
Dapagliflozin has been reported in several studies to possess lots of pharmacological activities, including anti-inflammatory, and apoptotic-modulation.
Faculty of Medicine, Zagazig University, Zagazig, Egypt
Zagazig, Zagazig, 34518, Egypt
First Submitted
October 22, 2026
First Posted
October 28, 2026
Study Start
October 30, 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Primary Completion
Niclosamide With Etanercept in Rheumatoid Arthritis
Contact the study team to confirm eligibility.
June 30, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
July 1, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
October 28, 2026
Record last verified: 2026-10
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: